TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03188809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral nerve block
Description: The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
Study: NCT04029792

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of plant extracts (BSL_EP028)
Description: Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
Study: NCT04491305

Intervention type: PROCEDURE
Intervention: Surgically treated women with endometriosis and confirmed diagnosis
Description: Women with indication for surgery or diagnostic laparoscopy will be enrolled in study.
Study: NCT00756600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
Study: NCT00284089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
Study: NCT03969082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Description: Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
Study: NCT00756600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
Study: NCT02322502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: inhalation with laryngeal mask to maintain anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhalation with laryngeal mask to maintain anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: intravenous injection to maintain anaesthesia
Study: NCT01959698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT02382796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
Study: NCT00637806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate concentrated suspension 110 mg/mL
Description: Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate concentrated suspension 60 mg/mL
Description: Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension, 5 mL once daily
Study: NCT04561297

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TDC differential value
Description: TDC measurements in all patients agreeing to participate who are scheduled for a biopsy of a breast tumor or mass
Study: NCT02888353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: MRI
Description: Perform MRI in patients with cardiac devices
Study: NCT01541670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Description: Intravenous injection
Study: NCT04029792

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
Study: NCT06729905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yerba mate tea
Description: Consumption of three cups per day of a beverage prepared with yerba mate

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control drink
Description: Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.
Study: NCT01087580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Prednisone
Description: A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Prednisone
Description: A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week.
Study: NCT05085106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac trometamol eye drop
Description: Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eye drop
Description: Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
Study: NCT01258075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose colesevelam
Description: 3.75 grams colesevelam hydrochloride in oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose colesevelam
Description: 0.625 grams colesevelam hydrochloride in oral suspension
Study: NCT03738800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 Cream 200 µg/g
Description: A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 Cream 100 µg/g
Description: A fixed dose (determined at Visit 1) of 100 µg/g applied topically twice weekly to up to 90% BSA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD5789 Cream Vehicle
Description: A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
Study: NCT04428203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex Oral Liquid Product
Description: patients with rising PSA after failure of localized therapy will receive Epidiolex PO once daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients receive an Epidiolex taper for 7-10 days after withdrawing from study for any reason or completion of the study period.
Study: NCT01194934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: 4 mg/kg daily IV for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: 2 mg/kg daily IV for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: 5 µg/kg SC daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12 in combination with Filgrastim
Description: Safe and efficacious dose regimen according to results of groups A and B
Study: NCT02359799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntelliStretch
Description: The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntelliStretch
Description: The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
Study: NCT02918552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
Study: NCT02758444

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Powder (MNP) + 15 mg Zn
Description: Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP + 10 mg Zn
Description: Same as above except MNP will contain 10 mg Zn

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP + 5 mg Zn
Description: Same as above except MNP will contain 5 mg Zn

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MNP without Zn
Description: Same as above except MNP will not contain Zn
Study: NCT05597579

Intervention type: DIAGNOSTIC_TEST
Intervention: DAPAR Tests (IQ equivalent test)
Description: This study will compare DAPAR scores before and after the onset of the psychotic illness.

Intervention type: DIAGNOSTIC_TEST
Intervention: DAPAR Tests (IQ equivalent test)
Description: This study will compare DAPAR scores before and after the onset of the psychotic illness.
Study: NCT00438802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
Study: NCT03535051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser
Description: Monthly fractional carbon dioxide laser sessions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Oint 0.03%
Description: topical daily tacrolimus ointment application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Oint 0.03%
Description: topical daily tacrolimus ointment application
Study: NCT01245868

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Study: NCT03978026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Each participant is compared to himself in 4 conditions,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Each participant is compared to himself in 4 conditions,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Each participant is compared to himself in 4 conditions,

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nap
Description: Each participant is compared to himself in 4 conditions,
Study: NCT02438150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital fire video training
Description: Participants will watch a video about hospital fire training which last for 30 minutes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non hospital fire video training
Description: Participants will watch a video about volcanic eruption which last for 30 minutes
Study: NCT03892369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Ethanol administration
Study: NCT03897205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
Study: NCT00637325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
Study: NCT04981184

Intervention type: DEVICE
Group type: OTHER
Intervention: Gait and balance measurement
Description: Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
Study: NCT01878136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
Study: NCT03371706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Bridge™
Description: Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based Impairment Focused
Description: Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
Study: NCT01239537

Intervention type: DRUG
Intervention: Seasonal Flu vaccine
Description: 1 dose of seasonal trivalent flu vaccine (Fluarix)

Intervention type: DRUG
Intervention: Seasonal Flu vaccine
Description: 1 dose of seasonal trivalent flu vaccine (Fluarix)
Study: NCT01193023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support
Description: Ventilation under pressure support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Ventilation under NAVA
Study: NCT04389918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tality
Description: Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
Study: NCT00874484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clexane (enoxaparin)
Description: One arm receives enoxoparin, second arm receives saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clexane (enoxaparin)
Description: One arm receives enoxoparin, second arm receives saline
Study: NCT00569036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
Study: NCT00339196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 azacytidine - VALPROIC acid- Retinoic acid
Description: 5 azacytidine - VALPROIC acid- Retinoic acid
Study: NCT00310466

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual immunotherapy
Description: once daily intake of sublingual drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily intake of sublingual drops
Study: NCT02898558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnification hand size
Description: Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnifying lenses
Study: NCT01643733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Flow measurements to guide fistula angioplasty (Transonics)
Description: Transonics flow measurements in the fistula would be used to guide the fistula intervention
Study: NCT03652116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration by Bupivacaine
Description: Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration by Pethidine
Description: Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
Study: NCT00508937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: 15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
Study: NCT02722837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT03526926

Intervention type: DRUG
Intervention: CPX-351
Description: VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
Study: NCT02252471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choices-Teen
Description: Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
Study: NCT03647605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Mind
Description: Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes.
Study: NCT00743938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-690514
Description: Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
Study: NCT01143064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid emulsion without progesterone
Description: Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
Study: NCT02638259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP2015
Description: Enbrel comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2015
Description: Enbrel comparator